Cardiovascular disease is a well-recognized cause of increased late morbidity and mortality among survivors of childhood cancer treated with anthracyclines. Co-administration of Dexrazoxane has been shown to significantly reduce short-term and mid-term cardiotoxicity. Aim of this study was to assess cardiac function in long-term (>10 years) survivors of childhood tumors treated with dexrazoxane/anthracycline association.
Echocardiographic long-term follow-up of adult survivors of pediatric cancer treated with dexrazoxane-anthracyclines association / Filomena, D.; Versacci, P.; Cimino, S.; Mattiucci, C.; Maestrini, V.; Cantisani, D.; Petronilli, V.; Agati, L.; Schiavetti, A.. - In: INTERNATIONAL JOURNAL OF CARDIOLOGY. - ISSN 1874-1754. - 2019:Aug 5(2019). [10.1016/j.ijcard.2019.07.096]
Echocardiographic long-term follow-up of adult survivors of pediatric cancer treated with dexrazoxane-anthracyclines association
Filomena D.
;Versacci P.;Cimino S.;Mattiucci C.;Maestrini V.;Cantisani D.;Petronilli V.;Agati L.;Schiavetti A.
2019
Abstract
Cardiovascular disease is a well-recognized cause of increased late morbidity and mortality among survivors of childhood cancer treated with anthracyclines. Co-administration of Dexrazoxane has been shown to significantly reduce short-term and mid-term cardiotoxicity. Aim of this study was to assess cardiac function in long-term (>10 years) survivors of childhood tumors treated with dexrazoxane/anthracycline association.| File | Dimensione | Formato | |
|---|---|---|---|
|
Filomena_Echocardiographic_2019.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
267.75 kB
Formato
Adobe PDF
|
267.75 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
